Publications

safety and immunogenicity of live attenuated influenza reassortant h5 vaccine (phase i-ii clinical trials).

our studies aimed to evaluate in clinical trials the safety and immunogenicity of an h5 live influenza vaccine candidate obtained using classical reassortment techniques from a low pathogenicity avian influenza (lpai) a/duck/potsdam/1402-6/86(h5n2) virus and the cold-adapted (ca) donor strain a/leningrad/134/17/57(h2n2).